# OnCo record nanolattix (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/nanolattix/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "nanolattix" ;
  schema:name "Nanolattix"@en ;
  schema:alternateName "Nanolattix Biotechnology Co., Ltd."@en, "Shanxi Naan Biological Technology Co., Ltd."@en, "山西纳安生物科技股份有限公司"@en, "纳安生物"@en ;
  schema:description "Nanolattix develops antibody-drug conjugates, which carry a cancer drug to tumour cells, and radioactive versions for scanning and treatment. Its lead medicine, T320, targets tissue factor, a protein found on many solid tumours, and is in early trials in China."@en ;
  schema:url <https://onco.cc/companies/nanolattix/>, <https://www.naanjt.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.naanjt.com/>, <http://en.naanjt.com/>, <https://clinicaltrials.gov/study/NCT07434609>, <https://clinicaltrials.gov/study/NCT07505069> ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/radiopharma/>, <https://onco.cc/fronts/imaging/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/immuno-pet/> ;
  onco:targets <https://onco.cc/targets/tissue-factor/> .